logo-loader
viewNaturally Splendid Enterprises Ltd.

Full interview: Naturally Splendid teams with Biologic Pharmamedical for a Phase 2 clinical study

Naturally Splendid (CVE: NSP- OTC: NSPDF) CEO Craig Goodwin and Biologic Pharmamedical CEO Franco Cavaleri joined Steve Darling from Proactive Vancouver to share details the two companies have formed a joint venture for the purpose of further developing and pursuing phase 2 clinical studies, utilizing one of Biologic's patented technologies as a candidate for a potential COVID 19 treatment.

Goodwin discusses the joint venture while Cavaleri shares the details about the study what the timing will look like.

Quick facts: Naturally Splendid Enterprises Ltd.

Price: 0.055 CAD

TSX-V:NSP
Market: TSX-V
Market Cap: $10.14 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Naturally Splendid Enterprises Ltd. named herein, including the promotion by the Company of Naturally Splendid Enterprises Ltd. in any Content...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Naturally Splendid releases 2019 financial numbers including a rise in revenue

Naturally Splendid (CVE: NSP- OTC: NSPDF) CEO Craig Goodwin joined Steve Darling from Proactive Vancouver with news the company saw a nice increase in revenue in 2019 as the company released their full-year numbers. Goodwin discusses those numbers and also how the changes they made last year,...

2 weeks, 6 days ago

2 min read